579 related articles for article (PubMed ID: 35857184)
21. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
23. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
[TBL] [Abstract][Full Text] [Related]
24. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
25. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
Hsieh MJ; Chen NH; Cheng SL; Tao CW; Wei YF; Wu YK; Chan MC; Liu SF; Hsu WH; Yang TM; Lin MS; Liu CL; Kuo PH; Tsai YH
Int J Chron Obstruct Pulmon Dis; 2022; 17():967-976. PubMed ID: 35510163
[TBL] [Abstract][Full Text] [Related]
26. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
27. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
Zheng J; Zhong N; Newlands A; Church A; Goh AH
Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
[TBL] [Abstract][Full Text] [Related]
29. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
[TBL] [Abstract][Full Text] [Related]
30. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
Feldman GJ; Edin A
Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
[TBL] [Abstract][Full Text] [Related]
31. Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD.
Maltais F; Vogelmeier CF; Kerwin EM; Bjermer LH; Jones PW; Boucot IH; Lipson DA; Tombs L; Compton C; Naya IP
Respir Med; 2022; 200():106918. PubMed ID: 35803172
[TBL] [Abstract][Full Text] [Related]
32. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
33. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
[TBL] [Abstract][Full Text] [Related]
35. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
[No Abstract] [Full Text] [Related]
36. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.
Schlueter M; Gonzalez-Rojas N; Baldwin M; Groenke L; Voss F; Reason T
Ther Adv Respir Dis; 2016 Apr; 10(2):89-104. PubMed ID: 26746383
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β
Czira A; Requena G; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():643-659. PubMed ID: 37155496
[TBL] [Abstract][Full Text] [Related]
38. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD.
Gong Y; Lv Y; Liu H; Zheng Q; Li L
Ther Adv Respir Dis; 2022; 16():17534666211066068. PubMed ID: 35001708
[TBL] [Abstract][Full Text] [Related]
39. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
Rodrigo GJ; Neffen H
Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():1431-1444. PubMed ID: 37465818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
